 RADNOR, Pa., Jan. 07, 2022 GLOBE NEWSWIRE -- NRx Pharmaceuticals NASDAQ: NRXP, a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Prof Jonathan Javitt, MD, MPH, will be presenting updates to the Companys business, including new details regarding late-stage trials of the investigational BriLifeTM COVID-19 vaccine at the H.C. Wainwright BioConnect Virtual Conference. 